Association between the methylenetetrahydrofolate reductase 677C-->T missense mutation and schizophrenia.
The schizophrenia phenotype is heterogeneous with respect to clinical presentation, long-term response to medication, and outcome, possibly reflecting genetic heterogeneity and/or the presence of modifier genes. Compared to non-responders, schizophrenic patients who are responders to neuroleptic medications are characterized by a high female/male ratio, a better long-term outcome and more frequently disturbed dopamine neurotransmission. In this study, we compared two groups of schizophrenic patients selected on the basis of their long-term response to neuroleptics (excellent responders and non-responders) and a group of healthy volunteers, with regard to a missense mutation (677C-->T) in the methylenetetrahydrofolate reductase (MTHFR) gene. This polymorphism was chosen because it is functional and was previously associated with schizophrenia. The present study revealed a significant association between schizophrenia and allele T of this gene. This association was entirely due to an over-representation of allele T in responder patients compared to controls; nonresponder patients did not differ from controls. Genotype TT was more frequent in responder patients compared to controls, thus replicating the findings of Arinami et al. These results strongly suggest that the MTHFR gene is involved in the pathogenesis of schizophrenia characterized by a rapid and sustained therapeutic response to typical neuroleptics and/or a good long-term prognosis/favorable therapeutic outcome.
Joober
R
R
Centre for Research in Neuroscience, Montreal General Hospital Research Institute, 1650 Cedar Avenue, Montreal H3G 1A4, Canada. rjoobe@po-box.mcgill.ca
Benkelfat
C
C
Lal
S
S
Bloom
D
D
Labelle
A
A
Lalonde
P
P
Turecki
G
G
Rozen
R
R
Rouleau
G A
GA
D000328:Adult; D000483:Alleles; D014150:Antipsychotic Agents / Q000627:therapeutic use; D003596:Cytosine; D005260:Female; D005838:Genotype; D006801:Humans; D008297:Male; D042965:Methylenetetrahydrofolate Reductase (NADPH2); D020125:Mutation, Missense; D000587:Oxidoreductases Acting on CH-NH Group Donors / Q000235:genetics*; D012559:Schizophrenia / Q000188:drug therapy / Q000201:enzymology* / Q000235:genetics*; D013941:Thymine
D014150:Antipsychotic Agents; D003596:Cytosine; D000587:Oxidoreductases Acting on CH-NH Group Donors; D042965:Methylenetetrahydrofolate Reductase (NADPH2); D013941:Thymine